CQS Cayman’s bluebird bio BLUE Stock Holding History

CQS Cayman’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,165	Closed	-$2.53M	–	116
2016 Q4	$2.53M	Hold	3,165	–	–	0.2%	76
2016 Q3	$2.78M	Buy	+3,165	New	+$2.29M	0.23%	68

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

CQS Cayman's BLUE Position: Q1 2017 in Review

CQS Cayman sold out of bluebird bio (BLUE) in Q1 2017, closing a stake of 3,165 shares — an estimated $2.53M sold.

CQS Cayman first reported a position in BLUE in Q3 2016 and held it in 2 quarters. The position peaked at $2.78M in Q3 2016. 210 funds tracked by Wall St. Rank hold BLUE as of Q1 2017.

CQS Cayman reported no remaining bluebird bio position as of Q1 2017 after selling out during the quarter.
CQS Cayman sold 3,165 bluebird bio shares in Q1 2017, an estimated $2.53M.
CQS Cayman first reported a position in bluebird bio in Q3 2016 and held it in 2 quarters.
CQS Cayman's bluebird bio position peaked at $2.78M in Q3 2016.
210 funds tracked by Wall St. Rank held bluebird bio as of Q1 2017.

Based on CQS Cayman's 13F filing for Q1 2017, filed 15 May 2017.